CD274 and cancer: Trial phase, line of treatment, cancer type, type of PD-1/PD-L1 inhibitor, and target of the combination agent were considered as categorial coefficients while the sources of heterogeneity remained challenging to fully elucidate and explain (Supplementary Table 4).